You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 3
  • 782 Survival in advanced-stage ovarian carcinoma with high VEGF-A expression after addition of bevacizumab. Results from the German ICON7 patient cohort

Article Text

Article menu

Download PDFPDF

Ovarian cancer
782 Survival in advanced-stage ovarian carcinoma with high VEGF-A expression after addition of bevacizumab. Results from the German ICON7 patient cohort
Free
  1. S Kommoss1,2,
  2. F Heitz2,3,
  3. L Serna-Higuita4,
  4. TW Park-Simon2,5,
  5. A Belau2,6,7,
  6. L Hanker2,8,
  7. KR Kimmig2,9,
  8. N De Gregorio2,10,
  9. B Schmalfeldt2,11,
  10. K Baumann2,12,
  11. W Schroeder2,13,
  12. U Canzler2,14,
  13. J Sehouli2,15,
  14. A Burges2,16,
  15. F Hilpert2,17,
  16. P Martus4,
  17. A Reuß18,
  18. S Mahner2,16,
  19. P Harter2,3 and
  20. J Pfisterer2,19
  1. 1Tübingen University Hospital, Department of Women’s Health, Tübingen, Germany
  2. 2AGO Study Group, Wiesabden, Germany
  3. 3Kliniken Essen-Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany
  4. 4Tuebingen University Hospital, Institut für Klinische Epidemiologie und angewandte Biometrie
  5. 5Hannover Medical School, Hannover, Germany
  6. 6Frauenarztpraxis Dr. Belau, Greifswald, Germany
  7. 7University Hospital Greifswald, Greifswald, Germany
  8. 8University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany
  9. 9University Hospital Essen, Essen, Germany
  10. 10SLK-Kliniken Heilbronn, Klinikum am Gesundbrunnen, Gynecology and Obstetrics, Heilbronn, Germany
  11. 11University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  12. 12Hospital Ludwigshafen, Gynecology and Obstetrics, Ludwigshafen, Germany
  13. 13Gynaekologicum Bremen, Bremen, Germany
  14. 14University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
  15. 15Charité – Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany
  16. 16University Hospital, LMU Munich, Department of Obstetrics and Gynecology, Munich, Germany
  17. 17Krankenhaus Jerusalem Hamburg, Hamburg, Germany
  18. 18Philipps-University Marburg, Coordinating Center for Clinical Trials, Marburg, Germany
  19. 19Gynecologic Oncology Center, Kiel, Germany

Abstract

Introduction/Background*It has previously been demonstrated that bevacizumab may differentially improve ovarian cancer survival. TCGA classification as well as molecular targets of anti-VEGF therapy were shown to be associated with different levels of bevacizumab efficacy. Translation into individualized treatment options or improved disease outcome was yet hindered by inconsistent results across trials and tissue types. It was the aim of this project to validate retrospective analyses of GOG-0218 derived predictive value of microvessel density (CD31) and tumor VEGF-A.

Methodology CD31 and VEGF-A immunohistochemistry was performed on whole section FFPE tissue samples from the AGO-OVAR11 (ICON7) trial. Patients were stratified into high and low biomarker-expressing subgroups using median cutoffs. The association between biomarker expression and bevacizumab therapy efficacy was evaluated using a proportional Cox regression model. Efficacy endpoints were progression free survival (PFS) and overall survival (OS).

Result(s)*Complete CD31 and VEGF-A immunhistochemical data were available from 387 patients of the German ICON7 trial cohort. Among all biomarker subgroups, only patients with high VEGF-A expression levels had a statistically significant benefit from the addition of bevacizumab to standard chemotherapy. Median PFS and OS of VEGF-A high patients was 23.1 months (95% CI 15.9-30.2) and 64.9 months (median not reached) respectively if bevacizumab was added to standard chemotherapy but only 14.3 (95% CI an 11.2-17) and 47.3 months (95% CI 5.6-36.3) in the control arm. In multivariable analysis, adjusted for age, FIGO and postoperative residual tumor, the anti-angiogenic therapy showed improved PFS (HR: 0.62 [95%CI 0.43-0.89], p=0.011) and OS (HR 0.59 [95%CI 0.39-0.91], p=0.02) among VEGF-A high patients. Patients with low VEGF-A expression levels showed no statistically significant improvement of PFS (HR 0.96 95% CI 0.67-1.38, p=0.83) or OS (HR 1.06 95% CI 0.69-1.62, p=0.80) after addition of bevacizumab. CD31 immunohistochemistry was not predictive for bevacizumab treatment effects in our cohort.

Conclusion*A potential predictive value of VEGF-A expression levels was observed in advanced stage ovarian carcinoma patients from the German ICON7 patient cohort, partly confirming GOG-0218 derived findings. Our results may help to develop biomarker stratified anti-VEGF therapy and hold potential to promote personalized treatment strategies in ovarian carcinoma patients.

https://doi.org/10.1136/ijgc-2021-ESGO.471

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.